Cited by 688Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy researchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Open access

Foust, Kevin D, Wang, Xueyong, McGovern, Vicki L, Braun, Lyndsey, Bevan, Adam K, Haidet, Amanda M, Le, Thanh T, Morales, Pablo R, Rich, Mark M, Burghes, Arthur H M, Kaspar, Brian K·2010·Nature Biotechnology

DOI 10.1038/nbt.1610PMC PMC2889698

Open this paper in CoChat — free account

Abstract

Spinal muscular atrophy (SMA), the most common autosomal recessive neurodegenerative disease affecting children, results in impaired motor neuron function. Despite knowledge of the pathogenic role of decreased survival motor neuron (SMN) protein levels, efforts to increase SMN have not resulted in a treatment for patients. We recently demonstrated that self-complementary adeno-associated virus 9 (scAAV9) can infect approximately 60% of motor neurons when injected intravenously into neonatal mice. Here we use scAAV9-mediated postnatal day 1 vascular gene delivery to replace SMN in SMA pups and rescue motor function, neuromuscular physiology and life span. Treatment on postnatal day 5 results in partial correction, whereas postnatal day 10 treatment has little effect, suggesting a developmental period in which scAAV9 therapy has maximal benefit. Notably, we also show extensive scAAV9-mediated motor neuron transduction after injection into a newborn cynomolgus macaque. This demonstration that scAAV9 traverses the blood-brain barrier in a nonhuman primate emphasizes the clinical potential of scAAV9 gene therapy for SMA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.1610This paper is marked retracted.

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Bénichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,995
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citation
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/- mice and results in a mouse with spinal muscular atrophy
Monani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 745
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Burghes, A. H. M., & Beattie, C. E. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2670 · Cited by 723
Self-citation
SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN
Le, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 600
Self-citation
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“Advances in vector design, such as AAV capsid modification, mutagenesis or gene shuffling, may expand the opportunity to target neurons in the adul”
BackgroundSelf-citation
Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511

Flagged first, then by citations

Show all 30 references

Sorted by citations

Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Self-citation
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 744
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
Spinal Muscular Atrophy
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 605
Spinal muscular atrophy
D’Amico, A., Mercuri, E. M., Tiziano, F. D., & Bertini, E. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-71 · Cited by 579
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J. E., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 560
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00001-6 · Cited by 494
Alternative Splicing in the Mammalian Nervous System: Recent Insights into Mechanisms and Functional Roles
Raj, B., & Blencowe, B. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.004 · Cited by 475
Spinal muscular atrophy: Diagnosis and management in a new therapeutic era
Arnold, W. D., Kassar, D., & Kissel, J. T. (2014) · Muscle & Nerve · doi:10.1002/mus.24497 · Cited by 436
Early Functional Impairment of Sensory-Motor Connectivity in a Mouse Model of Spinal Muscular Atrophy
Mentis, G. Z., Blivis, D., Liu, W., Drobac, E., Crowder, M. E., Kong, L., Álvarez, F. J., Sumner, C. J., & O'Donovan, M. J. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.032 · Cited by 395
Spinal muscular atrophy: going beyond the motor neuron
Hamilton, G., & Gillingwater, T. H. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.002 · Cited by 381
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 384
Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders
Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Self-citation
Spinal Muscular Atrophy
Kolb, S. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.74 · Cited by 335
Onasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337
Sphingolipid lysosomal storage disorders
Platt, F. M. (2014) · Nature · doi:10.1038/nature13476 · Cited by 318
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice
Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., de Moura, A. P., Voit, T., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq514 · Cited by 298
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S. A., Lehman, K. J., McColly, M., Lowes, L. P., Alfano, L. N., Reash, N. F., Iammarino, M. A., Church, K. R., Kleyn, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1272 · Cited by 295
Several rAAV Vectors Efficiently Cross the Blood–brain Barrier and Transduce Neurons and Astrocytes in the Neonatal Mouse Central Nervous System
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman Primates
Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286
Self-citation
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
Schorling, D., Pechmann, A., & Kirschner, J. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190424 · Cited by 304
Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?
Shababi, M., Lorson, C. L., & Rudnik‐Schöneborn, S. (2013) · Journal of Anatomy · doi:10.1111/joa.12083 · Cited by 263
Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285
Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery
Bors, L. A., & Erdő, F. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87010006 · Cited by 263
Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Wirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 267
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
Porensky, P. N., Mitrpant, C., McGovern, V. L., Bevan, A. K., Foust, K. D., Kaspar, B. K., Wilton, S. D., & Burghes, A. H. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr600 · Cited by 248
Self-citation
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Emerging therapies and challenges in spinal muscular atrophy
Farrar, M. A., Park, S. B., Vucic, S., Carey, K. A., Turner, B. J., Gillingwater, T. H., Swoboda, K. J., & Kiernan, M. C. (2016) · Annals of Neurology · doi:10.1002/ana.24864 · Cited by 246
Advances in therapy for spinal muscular atrophy: promises and challenges
Groen, E. J. N., Talbot, K., & Gillingwater, T. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.4 · Cited by 241
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy
Al‐Zaidy, S., Pickard, A. S., Kotha, K., Alfano, L. N., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D. M., Dabbous, O., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24203 · Cited by 216
Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10
Yang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213
Spinal Muscular Atrophies
Darras, B. T. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.010 · Cited by 214
Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
Bevan, A. K., Hutchinson, K. R., Foust, K. D., Braun, L., McGovern, V. L., Schmelzer, L., Ward, J. G., Petruska, J. C., Lucchesi, P. A., Burghes, A. H. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq300 · Cited by 211
Self-citation
Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation
Haery, L., Deverman, B. E., Matho, K. S., Cetin, A. H., Woodard, K., Cepko, C. L., Guerin, K. I., Rego, M. A., Ersing, I., Bächle, S. M., et al. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00093 · Cited by 220
Spinal muscular atrophy — insights and challenges in the treatment era
Mercuri, E. M., Pera, M. C., Scoto, M., Finkel, R. S., & Muntoni, F. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00413-4 · Cited by 220
Genetic Correction of Human Induced Pluripotent Stem Cells from Patients with Spinal Muscular Atrophy
Corti, S. P., Nizzardo, M., Simone, C., Falcone, M., Nardini, M., Ronchi, D., Donadoni, C., Salani, S., Riboldi, G. M., Magri, F., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004108 · Cited by 217
Survival Motor Neuron Protein in Motor Neurons Determines Synaptic Integrity in Spinal Muscular Atrophy
Martinez, T. L., Kong, L., Wang, X., Osborne, M. A., Crowder, M. E., Meerbeke, J. P. V., Xu, X., Davis, C., Wooley, J., Goldhamer, D. J., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0204-12.2012 · Cited by 206
Self-citation
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Van Alstyne, M., Tattoli, I., Delestrée, N., Recinos, Y., Workman, E., Shihabuddin, L. S., Zhang, C., Mentis, G. Z., & Pellizzoni, L. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00827-3 · Cited by 188
Targeted Delivery of Self-Complementary Adeno-Associated Virus Serotype 9 to the Brain, Using Magnetic Resonance Imaging-Guided Focused Ultrasound
Thévenot, E., Jordão, J. F., O’Reilly, M. A., Markham, K. A., Weng, Y., Foust, K. D., Kaspar, B. K., Hynynen, K., & Aubert, I. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.013 · Cited by 202
Self-citation
Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy
Ling, K., Gibbs, R. M., Feng, Z., & Ko, C. P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr453 · Cited by 201
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Ramos, D. M., d’Ydewalle, C. V. O., Gabbeta, V., Dakka, A., Klein, S., Norris, D. A., Matson, J. E., Taylor, S. J., Zaworski, P. G., Prior, T. W., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124120 · Cited by 198
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
Gene therapy for ALS: A review
Amado, D. A., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.008 · Cited by 203
Spinal Muscular Atrophy: A Clinical and Research Update
Markowitz, J. A., Singh, P., & Darras, B. T. (2011) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2011.09.001 · Cited by 191
One Year of Newborn Screening for SMA – Results of a German Pilot Project
Vill, K., Kölbel, H., Schwartz, O., Blaschek, A., Olgemöller, B., Harms, E., Burggraf, S., Röschinger, W., Durner, J., Gläser, D., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190428 · Cited by 188
Gene therapy for neurodegenerative disorders: advances, insights and prospects
Chen, W., Hu, Y., & Ju, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.015 · Cited by 198
Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy
Tisdale, S., & Pellizzoni, L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0417-15.2015 · Cited by 187
Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes
Hester, M. E., Murtha, M. J., Song, S., Rao, M., Miranda, C. J., Meyer, K., Tian, J., Boulting, G., Schaffer, D. V., Zhu, M. X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.135 · Cited by 183
Self-citation
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1
Al-Zaidy, S. A., & Mendell, J. R. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.06.007 · Cited by 189
Overcoming barriers to early disease intervention
Caicedo, H. H., Hashimoto, D. A., Caicedo, J. C., Pentland, A., & Pisano, G. P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0550-z · Cited by 181
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy
Lowes, L. P., Alfano, L. N., Arnold, W. D., Shell, R., Prior, T. W., McColly, M., Lehman, K. J., Church, K., Sproule, D. M., Nagendran, S., et al. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.05.005 · Cited by 179
In vivo genome editing improves motor function and extends survival in a mouse model of ALS
Gaj, T., Ojala, D. S., Ekman, F. K., Byrne, L. C., Limsirichai, P., & Schaffer, D. V. (2017) · Science Advances · doi:10.1126/sciadv.aar3952 · Cited by 185
Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction
Gogliotti, R. G., Quinlan, K. A., Barlow, C. B., Heier, C. R., Heckman, C. J., & DiDonato, C. J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5775-11.2012 · Cited by 177
Spinal Muscular Atrophy: In the Challenge Lies a Solution
Wirth, B. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.009 · Cited by 189
A multi-source approach to determine SMA incidence and research ready population
Verhaart, I. E. C., Robertson, A., Leary, R., McMacken, G., König, K., Kirschner, J., Jones, C. C., Cook, S. F., & Lochmüller, H. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8549-1 · Cited by 173
Antisense-based therapy for the treatment of spinal muscular atrophy
Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201207087 · Cited by 178
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy
Lutz, C. M., Kariya, S., Patruni, S., Osborne, M. A., Liu, D., Henderson, C. E., Li, D. K., Pellizzoni, L., Rojas, J. L. V., Valenzuela, D. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57291 · Cited by 168
MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression
Xie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J., Su, Q., He, R., Mu, X. N., Ahmed, S. S., Park, S., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.279 · Cited by 169
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
Chaytow, H., Faller, K. M. E., Huang, Y.-T., & Gillingwater, T. H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100346 · Cited by 179
Structural basis of a small molecule targeting RNA for a specific splicing correction
Campagne, S., Boigner, S., Rüdisser, S., Moursy, A., Gillioz, L., Knörlein, A., Hall, J., Ratni, H., Cléry, A., & Allain, F. H. ‐. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0384-5 · Cited by 165
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Vill, K., Schwartz, O., Blaschek, A., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Czibere, L., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01783-8 · Cited by 165
Reduced Survival of Motor Neuron (SMN) Protein in Motor Neuronal Progenitors Functions Cell Autonomously to Cause Spinal Muscular Atrophy in Model Mice Expressing the Human Centromeric ( SMN2 ) Gene
Park, G.-H., Maeno-Hikichi, Y., Awano, T., Landmesser, L. T., & Monani, U. R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2208-10.2010 · Cited by 164
Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
Crawford, T. O., Paushkin, S. V., Kobayashi, D. T., Forrest, S. J., Joyce, C. L., Finkel, R. S., Kaufmann, P., Swoboda, K. J., Tiziano, F. D., Lomastro, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033572 · Cited by 158
Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production
McGivern, J. V., Patitucci, T. N., Nord, J. A., Barabas, M. E., Stucky, C. L., & Ebert, A. D. (2013) · Glia · doi:10.1002/glia.22522 · Cited by 156
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Nishio, H., Niba, E. T. E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511939 · Cited by 183
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Messina, S., & Sframeli, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072222 · Cited by 165
Targeting RNA to treat neuromuscular disease
Muntoni, F., & Wood, M. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3459 · Cited by 156
Aging brain microenvironment decreases hippocampal neurogenesis through Wnt‐mediated survivin signaling
Miranda, C. J., Braun, L., Jiang, Y., Hester, M. E., Zhang, L., Riolo, M., Wang, H., Rao, M., Altura, R. A., & Kaspar, B. K. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00816.x · Cited by 153
Self-citation
Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation
Kariya, S., Obis, T., Garone, C., Akay, T., Sera, F., Iwata, S., Homma, S., & Monani, U. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72017 · Cited by 150
Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice
Xie, Y., Zhou, B., Lin, M.-Y., Wang, S., Foust, K. D., & Sheng, Z.-H. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.026 · Cited by 149
Self-citation
A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology
Bowerman, M., Murray, L. M., Beauvais, A., Pinheiro, B., & Kothary, R. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.09.007 · Cited by 148
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
Pechmann, A., Langer, T., Schorling, D., Stein, S., Vogt, S., Schara, U., Kölbel, H., Schwartz, O., Hahn, A., Giese, K., et al. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180315 · Cited by 149
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. J., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 144
New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093297 · Cited by 157
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
Spinal muscular atrophy: A changing phenotype beyond the clinical trials
Tizzano, E. F., & Finkel, R. S. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.05.011 · Cited by 139
Spinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138
A large animal model of spinal muscular atrophy and correction of phenotype
Duqué, S. I., Arnold, W. D., Odermatt, P., Li, X., Porensky, P. N., Schmelzer, L., Meyer, K., Kolb, S. J., Schümperli, D., Kaspar, B. K., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24332 · Cited by 148
Self-citation
Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation in Spinal Muscular Atrophy
Ng, S., Soh, B.-S., Rodríguez‐Muela, N., Hendrickson, D. G., Price, F. D., Rinn, J. L., & Rubin, L. L. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.003 · Cited by 132
AAV4-mediated Expression of IGF-1 and VEGF Within Cellular Components of the Ventricular System Improves Survival Outcome in Familial ALS Mice
Dodge, J. C., Treleaven, C. M., Fidler, J. A., Hester, M. E., Haidet, A. M., Handy, C. R., Rao, M., Eagle, A., Cowger, J. A., Taksir, T. V., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.206 · Cited by 130
Self-citation
Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons
Lee, Y. I., Mikesh, M., Smith, I., Rimer, M., & Thompson, W. J. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.05.667 · Cited by 130
Temporal requirement for high SMN expression in SMA mice
Le, T. T., McGovern, V. L., Alwine, I. E., Wang, X., Massoni‐Laporte, A., Rich, M. M., & Burghes, A. H. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr275 · Cited by 130
Self-citation
Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
Waldrop, M. A., Karingada, C., Storey, M. A., Powers, B. R., Iammarino, M. A., Miller, N. F., Alfano, L. N., Noritz, G. H., Rossman, I. T., Ginsberg, M., et al. (2020) · PEDIATRICS · doi:10.1542/peds.2020-0729 · Cited by 134
Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality
Ackermann, B., Kröber, S., Torres‐Benito, L., Borgmann, A., Peters, M., Hosseinibarkooie, S., Tejero, R., Jakubik, M., Schreml, J., Milbradt, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds540 · Cited by 129
Intramuscular scAAV9-SMN Injection Mediates Widespread Gene Delivery to the Spinal Cord and Decreases Disease Severity in SMA Mice
Benkhelifa‐Ziyyat, S., Besse, A., Roda, M., Duqué, S. I., Astord, S., Carcenac, R., Marais, T., & Barkats, M. (2013) · Molecular Therapy · doi:10.1038/mt.2012.261 · Cited by 128
Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain
López‐Bastida, J., Peña-Longobardo, L. M., Aranda-Reneo, I., Tizzano, E. F., Sefton, M., & Oliva, J. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0695-0 · Cited by 128
New treatments in spinal muscular atrophy: an overview of currently available data
Ramdas, S., & Servais, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1704732 · Cited by 132
Gene therapy for neurodegenerative diseases
O’Connor, D. M., & Boulis, N. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.06.001 · Cited by 135
The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
Sleigh, J. N., Gillingwater, T. H., & Talbot, K. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007245 · Cited by 126
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 152
AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy
Morabito, G., Giannelli, S. G., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M. T., Cabassi, T., Cattaneo, S., Luoni, M., Cancellieri, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.004 · Cited by 128

Authors: Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., & Kaspar, B. K.
Affiliations: Nationwide Children's Hospital (US)
Wright State University (US)
The Ohio State University (US)
Corresponding author: Kaspar, Brian K
ORCID: Foust, Kevin D
Wang, Xueyong
McGovern, Vicki L
Le, Thanh T
Morales, Pablo R
Rich, Mark M
Burghes, Arthur H M
Kaspar, Brian K
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2010-02-28
Volume: 28
Issue: 3
Pages: 271-274
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.1610
PMC: PMC2889698
OpenAlex: W2045117117
Cited by: 688
References: 30
Citations by year: 2026: 5 · 2025: 10 · 2024: 17 · 2023: 19 · 2022: 42 · 2021: 49 · 2020: 61 · 2019: 51 · 2018: 32 · 2017: 56 · 2016: 48 · 2015: 51 · 2014: 57 · 2013: 54 · 2012: 48
FWCI: 27.28
Type: journal article
Language: en
Status: Retracted
Update notices: retraction (2022-10-06)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
CORE Scholar (Wright State University) (submittedVersion)
Journal of Bioresource Management (submittedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R21NS064328, RC2NS069476, P30NS045758, P01NS057228, R01NS038650, F31NS058224)
Topics: Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: spinal muscular atrophy, gene therapy, motor neurons, blood-brain barrier, cynomolgus macaques, mouse model, retraction
MeSH terms: Dependovirus, Animals, Animals, Newborn, Disease Models, Animal, Macaca fascicularis, Male, Mice, Transgenic, Microscopy, Fluorescence, Motor Neurons, Muscular Atrophy, Spinal, Phenotype, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Kaplan-Meier Estimate, Survival of Motor Neuron 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks